Immune globulin subcutaneous (Human, IGSC)

N/A

Report date: 2023/11/23 17:35:27

Base Information

Drug NameImmune globulin subcutaneous (Human, IGSC)
Drug Alias Name人类皮下免疫球蛋白（IGSC）CuvitruCUVITRU
ClassificationBiologics > Blood components
Mechanisms of ActionImmunomodulatorsAmyloid beta-protein precursor inhibitors
TargetsAmyloid beta-protein precursor
Therapy Area/IndicationsImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesAgammaglobulinemia +[6] 
Global Approved IndicationsImmunologic Deficiency SyndromesAgammaglobulinemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/09/13
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxalta Incorporated
China Registration ClassN/A

Develop Information

Active CompaniesBaxalta IncorporatedTakeda Pharmaceutical Co LtdUniversity Health Network (Uhn)
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesPrimary Immunodeficiency DiseasesAgammaglobulinemia +[5] 
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeJ06BA01
Related LinksDrugBank